PAO Group, Inc. (OTC Pink: PAOG) looks ready to run. Its YTD developments have been promising, but its July updates appear to position PAOG for a breakout sooner rather than later.
Earlier in the month, the company posted a detailed report on its latest developments in the commercialization of its CBD-based nutraceutical product line. The best part of that update was PAOG's reiteration that its potentially market-changing CBD-based nutraceuticals will be commercially available by the end of 2021. For investors, that may be the most critical takeaways from the report.
Important too, of course, is that its products could be some of the first to treat critical health indications.
PAOG's RespRX Targets COPD Treatment
RespRX is the first product in PAOG's portfolio and is considered the company's lead program. RespRx utilizes CBD-based therapeutics to treat the symptoms of chronic obstructive pulmonary disease (COPD). The treatment targets a multi-billion-dollar opportunity, leveraging studies conducted in 2015 that suggest CBD could help open the bronchial passages. This discovery could prove transformational as CBD is well tolerated and lacks the often severe side effects associated with current standards of care. In fact, many believe that once the right CBD-based alternative comes to market, it could become a preferred method of treatment in the sector. And, with RespRX, PAOG thinks it can win a significant portion of that prize.
The more excellent news is that PAOG's RespRX is already demonstrating its potential. The CBD-based compound is derived from a patented process of extracting cannabidiol - "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT" (US Patent No. 9,199,960) - and produces an extract said to rival the quality of one of the industry's pioneers, GW Pharma (NASDAQ: GWHP). Best of all, PAOG would be able to monetize the RespRX platform and extraction process through licensing agreements, maximizing the value of this IP.
This opens up a significant revenue stream for PAOG through potential third-party agreements, which could be used to fund additional product development. It's a win-win situation for everyone involved. However, should one of its treatments complete its clinical studies demonstrating a significant benefit, expect PAOG to attract investors and continue forward on its own to maximize profits.
While RespRx might be its lead program, speculation is mounting that its other CBD nutraceutical may actually beat it to the market. That one, too, brings substantial market opportunities.
Targeting The Biggest Opportunities in the CBD Sector
Leveraging its patented extraction process, PAOG can concurrently develop other CBD-based treatments that target some of the industry's most lucrative sectors.
A big reward could come through its CBD RELAX-RX, which targets patient treatment in the $15 billion anxiety and depression market. Its promise stems from the trend of an increasing number of patients opting for CBD-based treatments over pharmaceuticals to treat the often debilitating symptoms of depression and anxiety. PAOG believes that it's CBD RELAX-RX, specially formulated for this application, can provide a best-in-class solution, and its patented extraction process backs up that claim.
While the nutraceuticals can deliver massive rewards, so can PAOG's other interests and partnerships. EVERx CBDSports water is one example.
EVERx CBD Sports Water
PAOG is also well into the process of advancing what could become a staple in its revenue-generating arsenal, EVERx CBD Sports Water. In a joint venture with Puration, Inc. (OTC Pink: PURA), that product is already generating revenues, with sales reaching upwards of $1 million before the pandemic virtually closing down the markets. However, with markets coming back online, expect updates from that interest to surprise to the upside. It should; it's a great product.
And it's taking advantage of market trends that show a rise in CBD sales and a decrease in soda consumption. Thus, EVERx CBD Sports Water capitalizes upon both of these trends, and better still, the planned addition of a sugar-free variety should enhance the offering and accelerate the brand's expansion across store shelves nationwide.
The best news of all is that PAOG's CBD-based products and nutraceuticals are expected to begin generating revenues this year. Even better, they are high-margin sales. And if PAOG meets its expected delivery throughout its pipeline initiatives, expect PAOG's share price to increase exponentially. Like most nano-caps- if investors see revenues, PAOG could indeed be off to the races.
A Potential Surge In 2H 2021
Keep an eye on PAOG in the back half of this year and know that at least two revenue-generating catalysts could be near. Hence, news can be an investor's best friend when it comes to PAOG over the next three to six months. And give PAOG a bit of a break. As many investors in the biotech sector know, trials can take twists and turns. With that being said, however, PAOG's commitment to stay true to its timeline is an encouraging indicator that a catalyst is forthcoming.
The bottom line is getting simpler to understand. With several catalysts in front of them and multiple products in its pipeline, PAOG is positioned for a breakout. And while its CBD Nutraceuticals program gets the bulk of the attention, its other interests are compelling as well. Thus, consider an investment in PAOG a diversified commitment.
Better still, that diversity offers several shots on revenue-generating goals, making PAOG attractive on multiple levels. That's good, too.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Hawk Point Media was compensated up to five-thousand-dollars by a third-party to research, prepare, and syndicate written and visual content about Gourmet Provisions International Corp. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found by clicking HERE.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name:Hawk Point Media
Contact Person: Ken Lawrence
Email:info@hawkpointmedia.com
Phone: 3057806988
City: Miami Beach
State: Florida
Country: United States
Website: https://paonutraceuticals.com/
